Comparison of Thrombolytic Therapies With Mutant tPA (Lanoteplase/SUN9216) and Recombinant tPA (Alteplase) for Acute Myocardial Infarction
نویسندگان
چکیده
منابع مشابه
Comparison of thrombolytic therapies with mutant tPA (lanoteplase/SUN9216) and recombinant tPA (alteplase) for acute myocardial infarction.
The fibrinolytic capacity of patients with acute myocardial infarction (AMI) is known to be impaired. The primary regulatory element of the fibrinolytic system is plasminogen activator inhibitor (PAI). It has been previously observed that there are 2 peaks in the plasma PAI level of AMI patients at 4h and 16h after thrombolytic therapy with recombinant tissue plasminogen activator (rtPA). Lanot...
متن کاملA comparison of reteplase with alteplase for acute myocardial infarction.
BACKGROUND Reteplase (recombinant plasminogen activator), a mutant of alteplase tissue plasminogen activator, has a longer half-life than its parent molecule and produced superior angiographic results in pilot studies of acute myocardial infarction. In this large clinical trial, we compared the efficacy and safety of these two thrombolytic agents. METHODS A total of 15,059 patients from 807 h...
متن کاملAdministering Intravenous Alteplase (Tissue Plasminogen Activator [tPA])
Step 1: Eligibility-The eligibility criteria for patients with acute ischemic stroke within 3 hours of symptom onset include: • An adult (> 18 years of age) • Exclusion of intrancranial hemorrhage by an imaging technique sensitive for the presence of hemorrhage • Arrives at the emergency department in time to be treated within 3 hours of symptom onset • The recommended dose of IV tPA is 0.9 mg/...
متن کاملPlatelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase.
BACKGROUND Changes in platelet aggregation (PA) and platelet surface receptor expression induced by thrombolytic therapy for acute myocardial infarction may influence the rate of initial reperfusion and early reocclusion. METHODS AND RESULTS In the RAPID-1 (Reteplase Angiographic Phase II International Dose-finding study), RAPID-2 (Reteplase vs Alteplase Patency Investigation During myocardia...
متن کاملPrimary PTCA versus thrombolysis with tPA in acute myocardial infarction: a formal cost-effectiveness analysis.
AIMS Information concerning the cost-effectiveness of primary percutaneous transluminal coronary angioplasty (PTCA) compared to thrombolytic treatment with tissue plasminogen activator (tPA) for the management of acute myocardial infarction (AMI) is limited. The existing data are derived from studies using a wide range of intervention, re-intervention and a high rate of mortality. The present s...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Circulation Journal
سال: 1998
ISSN: 0047-1828,1347-4839
DOI: 10.1253/jcj.62.801